1 October 2026
Electra Therapeutics (ETRA)
IPO 18 September 2026
The company
Electra Therapeutics is a clinical-stage biotechnology company developing therapies for serious immunological diseases. Its lead candidate, ELA026, is a monoclonal antibody designed to deplete SIRP-positive immune cells and is being developed for secondary hemophagocytic lymphohistiocytosis. The company intends to use the IPO proceeds primarily to support ELA026 and the advancement of its broader clinical pipeline.
Competitors and market
Electra competes with existing immunosuppressive regimens and experimental therapies for severe hyperinflammatory and immune-mediated diseases. Its commercial potential depends heavily on ELA026 demonstrating a meaningful clinical benefit over combinations of steroids, chemotherapy and targeted immunotherapies. The IPO was upsized from approximately 21.7 million to 23.3 million shares and priced at the midpoint of its $14–16 range, indicating solid initial demand. The subsequent decline of more than 24% from the offer price shows that investors remain cautious about a pre-revenue biotechnology company with a concentrated pipeline.
Price action
- IPO price: $15.00 per share
- Offering size: 23,333,334 shares for gross proceeds of approximately $350 million
- First day, 18 September: closed at $13.25, approximately 11.7% below the IPO price, after reaching an intraday high of $15.50
- Latest verified price: $11.32 at the 28 September close, with a market capitalization of approximately $710.52 million
- Performance from IPO price: approximately −24.5%
- Performance from first-day close: approximately −14.6%
- Post-IPO range: $11.14–15.50
- Underwriter option: up to 3,500,000 additional shares
Electra declined during most of its first nine trading sessions and was approximately 4% above its post-IPO low at the latest verified close. The first-day high of $15.50 has not been revisited, leaving the stock with a clearly negative technical profile below the offer price.
Conclusion and what to expect
Electra has raised approximately $350 million but remains a pre-revenue biotechnology company with a market capitalization of about $711 million. Its investment case is highly dependent on ELA026, making clinical progress and safety data the most important fundamental variables. The lock-up expiration was not independently verified, although a customary 180-day period from the 17 September prospectus would end around 16 March 2027. The nearest potential catalyst is the end of the quiet period around 13 October, when Jefferies, TD Cowen, Evercore ISI and Cantor Fitzgerald could initiate research coverage.
Read more about ETRA.US on the TFOS platform
Orion180 (OIG)
IPO 18 September 2026
The company
Orion180 is a technology-focused insurance company specializing in excess and surplus lines homeowners coverage. It describes itself as the second-largest US excess and surplus lines homeowners insurer by direct written premiums. The company operates in 14 states and distributes its products through more than 14,000 active independent agents.
Competitors and market
Orion180 competes with traditional property insurers, specialist excess and surplus carriers and technology-enabled insurance platforms. Its growth opportunity is being supported by reduced insurance availability in catastrophe-exposed regions, although this also increases its exposure to severe weather and reinsurance costs. The IPO priced at $12, well below the initially targeted $15–17 range, indicating weaker-than-expected institutional demand. The continued decline after listing suggests that investors remain unwilling to pay a large valuation premium until Orion180 establishes a longer public record of profitable growth.
Price action
- IPO price: $12.00 per share, below the initially targeted $15–17 range
- Offering size: 20,000,000 Class A shares for gross proceeds of $240 million
- First day, 18 September: closed at $11.77, approximately 1.9% below the IPO price
- Latest verified price: $9.64 at the 30 September close, down 5.3% for the session
- Performance from IPO price: approximately −19.7%
- Performance from first-day close: approximately −18.1%
- Post-IPO range: approximately $9.50–12.06
- Underwriter option: up to 3,000,000 additional shares
Orion180 has remained under pressure since its below-range pricing and was trading close to the bottom of its post-IPO range at the latest verified close. The stock has not established technical support, and the decline from both the offer price and first-day close points to continued selling pressure.
Conclusion and what to expect
Orion180 reported revenue of $153.14 million and net income of $32.25 million, with its net margin improving to 21.1% from approximately 7% a year earlier. Even after the decline to $9.64, its estimated price-to-earnings ratio of approximately 29.6 times remains above the cited direct-peer and broader insurance-industry averages. The 180-day lock-up covering directors, executives and substantially all existing shareholders is estimated to expire around 16 March 2027. Over the coming months, investors will focus on catastrophe losses, reinsurance expenses, the first public-company results and potential analyst initiations from RBC Capital Markets, UBS and Raymond James.
Read more about OIG.US on the TFOS platform
ADARx Pharmaceuticals (ADRX)
IPO 25 September 2026
The company
ADARx Pharmaceuticals is a clinical-stage biotechnology company developing RNA-targeted medicines for genetically defined and complex diseases. Its lead candidate, onvuzosiran, is in late-stage development for hereditary angioedema. The company also has a major siRNA partnership with AbbVie, which paid $335 million upfront in 2025 and invested approximately $89.3 million alongside the IPO.
Competitors and market
ADARx competes with established and experimental treatments for hereditary angioedema, including injectable prophylactic therapies and emerging oral medicines. It also competes with other biotechnology companies developing RNA-interference platforms for complement-mediated and genetically defined diseases. Investor demand was strong enough for the company to increase its offering from approximately 21.9 million to 26.3 million shares and price at the top of its $15–17 range. The shares remained above the offer price after four trading sessions, making ADRX the strongest-performing completed IPO in this group.
Price action
- IPO price: $17.00 per share
- Offering size: 26,250,000 shares, increased from the earlier plan for approximately 21,900,000 shares
- First day, 25 September: opened at $22.10 and closed at $19.35, representing gains of 30.0% and 13.8%, respectively
- Post-IPO high: $23.21, reached during the first session
- Latest verified price: $20.64 at the 29 September close, with a market capitalization of approximately $2.20 billion
- Performance from IPO price: approximately +21.4%
- Performance from first-day close: approximately +6.7%
- Post-IPO range: $18.50–23.21
- Underwriter option: up to 3,937,500 additional shares
ADARx retained most of its initial premium and was trading near the middle of its brief post-IPO range at the latest verified close. A conventional two-week return cannot yet be calculated because the stock had completed only four trading sessions.
Conclusion and what to expect
ADARx completed the strongest offering in the group, raising substantial capital while receiving additional validation from AbbVie’s concurrent investment. Its approximately $2.2 billion market capitalization reflects the potential of its RNA pipeline rather than current profitability, as trailing net income was negative $87.87 million. The lock-up expiration was not confirmed, although a customary 180-day period from the 24 September prospectus would end around 23 March 2027. The nearest potential catalysts are analyst initiations after approximately 20 October and further progress with onvuzosiran, while the main risks are clinical disappointment and profit-taking by investors allocated shares at $17.
Read more about ADRX.US on the TFOS platform
Prices and performance figures in the text are as at the dates stated; charts and panels are TFOS platform snapshots of 1 October 2026 and can show later prices. Marketing communication, not independent investment research and not financial advice. Past performance is not a guide to future results. Turlov Family Office Securities (Pty) Ltd is an authorised FSP (52874).